Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it.

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by ...

Smith and Winter’s work on a technique known as phage display was notably used to develop Humira (adalimumab), first approved in 2002 and now used in a range of inflammatory diseases.

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...